Home | All trials

[RDF data]
Trial NCT00000225

Resource URI: http://static.linkedct.org/resource/trials/NCT00000225
PropertyValue
linkedct:brief_title Alternate-Day Buprenorphine Administration. Phase VI - 7
linkedct:collaborator_agency <http://static.linkedct.org/resource/collabagency/8908>
linkedct:condition <http://static.linkedct.org/resource/condition/9249>
linkedct:criteria Please contact site for information.
linkedct:download_date Information obtained from ClinicalTrials.gov on December 30, 2009
linkedct:eligibility_gender Both
linkedct:eligibility_healthy_volunteers No
linkedct:eligibility_maximum_age 51 Years
linkedct:eligibility_minimum_age 21 Years
linkedct:enrollment 0 (xsd:int)
linkedct:firstreceived_date September 20, 1999
linkedct:id NCT00000225
rdfs:label Trial NCT00000225
linkedct:lastchanged_date June 23, 2005
linkedct:lead_sponsor_agency National Institute on Drug Abuse (NIDA)
linkedct:location <http://static.linkedct.org/resource/location/149541>
linkedct:nct_id NCT00000225
linkedct:number_of_arms 0 (xsd:int)
linkedct:number_of_groups 0 (xsd:int)
linkedct:official_title Alternate-Day Buprenorphine Administration. Phase VI
linkedct:org_study_id NIDA-06969-7
linkedct:overall_official <http://static.linkedct.org/resource/overall_official/60820>
linkedct:overall_status Completed
linkedct:oversight <http://static.linkedct.org/resource/oversight/2918>
foaf:page <http://clinicaltrials.gov/show/NCT00000225>
linkedct:phase Phase 2
linkedct:primary_outcomes <http://static.linkedct.org/resource/primary_outcomes/14369>
linkedct:primary_outcomes <http://static.linkedct.org/resource/primary_outcomes/14376>
linkedct:primary_outcomes <http://static.linkedct.org/resource/primary_outcomes/17569>
linkedct:primary_outcomes <http://static.linkedct.org/resource/primary_outcomes/7149>
linkedct:primary_outcomes <http://static.linkedct.org/resource/primary_outcomes/7287>
linkedct:secondary_id R01-06969-7
linkedct:source National Institute on Drug Abuse (NIDA)
linkedct:start_date December 1992
linkedct:study_design Treatment, Double-Blind, Placebo Control
linkedct:study_type Interventional
linkedct:summary The purpose of this study is to determine if four times a subject's daily maintenance dose will hold for 96 hours without changes in agonist and antagonist effects.
rdf:type linkedct:trials
linkedct:verification_date June 2004